Drug Profile
Research programme: serotonin receptor-targeted therapeutics - Neurolixis
Alternative Names: F-13640 - Neurolixis; F-15599 - NeurolixisLatest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer Neurolixis
- Class Non-opioid analgesics; Piperidines; Pyridines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Drug-induced dyskinesia; Rett syndrome
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Rett syndrome in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Drug-induced-dyskinesia in USA
- 06 Mar 2014 Research programme: serotonin receptor-targeted therapeutics - Neurolixis receives Orphan Drug status for Rett syndrome in European Union